MMSI
Merit Medical Systems, Inc.
MMSI has the edge over NVO overall, supported by stronger valuation and stronger modeled upside.
NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
MMSI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
MMSI's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
MMSI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $86.69 | — |
| Current | 32x | $86.69 | — |
| Cheap | 42x | $112 | +29% |
| Fair | 49x | $132 | +52% |
| Expensive | 84x | $223 | +157% |
Historical ranges are pointers, not guarantees.
MMSI's PE is in its cheap range at 32x. If earnings grow as analysts expect, today's price would be 19x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over MMSI in the historical PE scenario, which offers more potential upside but is not a forecast.
MMSI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
MMSI has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
MMSI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.49 | +68% |
| Q3 2026 | $2.67 | +37% |
| Q2 2026 | $2.43 | +23% |
| Q1 2026 | $2.32 | +14% |
| Q4 2025 | $2.13 | +4.9% |
| Q3 2025 | $1.95 | -4.4% |
| Q2 2025 | $1.97 | -1.5% |
| Q1 2025 | $2.04 | +17% |
| Q4 2024 | $2.03 | +25% |
MMSI earned $2.67 per share over the past year, up 37% from the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over MMSI on earnings, with more consistent year-over-year improvement.
MMSI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $416.2M | +8.4% |
| Q2 2026 | $418.8M | +9.5% |
| Q1 2026 | $381.9M | +7.5% |
| Q4 2025 | $393.9M | +11% |
| Q3 2025 | $384.2M | +13% |
| Q2 2025 | $382.5M | +13% |
| Q1 2025 | $355.4M | +9.8% |
| Q4 2024 | $355.2M | +9.4% |
MMSI's revenue has grown year over year every quarter since late 2020: $416M last quarter, up 8.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +3 points |
| Q2 2026 | 14% | +2.2 points |
| Q1 2026 | 12% | 0 points |
| Q4 2025 | 14% | +3.5 points |
| Q3 2025 | 11% | +0.1 points |
| Q2 2025 | 12% | -1.3 points |
| Q1 2025 | 12% | +0.5 points |
| Q4 2024 | 10% | -0.1 points |
MMSI's operating margin was 14% last quarter, up 3 points from the same quarter a year ago, near the top of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over MMSI on profitability, with a higher operating margin.
MMSI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $52.9M | +0.7% |
| Q2 2026 | $51.9M | -25% |
| Q1 2026 | $24.7M | +26% |
| Q4 2025 | $74M | +13% |
| Q3 2025 | $52.5M | +38% |
| Q2 2025 | $69.6M | +20% |
| Q1 2025 | $19.5M | -20% |
| Q4 2024 | $65.3M | +18% |
MMSI has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
MMSI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +373K shares |
| 1 year | +0.8% | +460K shares |
| 3 years | +3.4% | +2M shares |
| 5 years | +4.9% | +2.8M shares |
| Available history | +7.4% | +4.1M shares |
MMSI has 60M diluted shares, up 0.8% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over MMSI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
MMSI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.9x | Very low |
| Q1 2026 | 0.8x | Very low |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 1.4x | Healthy |
MMSI's net debt is less than a year of its operating earnings (EBITDA), down from 1.2 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over MMSI on leverage, with a lower net debt burden relative to earnings.
MMSI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.9 | Neutral |
| Stochastic | 40.0 | Neutral |
MMSI's weekly RSI is 56 (neutral) and its Stochastic is 40 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
MMSI PE vs Healthcare Sector
| Metric | MMSI | Sector median | Relative |
|---|---|---|---|
| PE | 32x | 26x | 26% above |
| PE % | 6 | 29 | 23 pts below |
MMSI is trading at 32x earnings, a 26% premium to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over MMSI on valuation relative to its sector.
MMSI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $87.8 | 1.3% below |
| 20 week MA | $85.2 | 1.8% above |
| 50 week MA | $78.5 | 10% above |
| 100 week MA | $85.8 | 1.1% above |
| 200 week MA | $82.9 | 4.5% above |
MMSI has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
MMSI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $31.3 | $54.5 | +74% |
| 2021 | $54.5 | $63.7 | +17% |
| 2022 | $63.7 | $70.9 | +11% |
| 2023 | $70.9 | $76.0 | +7.2% |
| 2024 | $76.0 | $97.3 | +28% |
| 2025 | $97.3 | $87.4 | -10% |
| 2026 YTD | $87.4 | $86.7 | -0.8% |
MMSI has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.